Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 25;13(10):12153-68.
doi: 10.3390/ijms131012153.

Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K Arrington  1 , Eileen L Heinrich, Wendy Lee, Marjun Duldulao, Supriya Patel, Julian Sanchez, Julio Garcia-Aguilar, Joseph Kim
Affiliations
Review

Prognostic and predictive roles of KRAS mutation in colorectal cancer

Amanda K Arrington et al. Int J Mol Sci. .

Abstract

The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The Ras Activation Cascade.
Figure 2
Figure 2
Constitutional Activation of KRAS.
Figure 3
Figure 3
EGFR Signaling and KRAS/BRAF Interaction.
See this image and copyright information in PMC

References

    1. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant C-K-Ras genes. Cell. 1988;53:549–554. - PubMed
    1. De Roock W., Piessevaux H., de Schutter J., Janssens M., de Hertogh G., Personeni N., Biesmans B., van Laethem J.L., Peeters M., Humblet Y., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008;19:508–515. - PubMed
    1. Bell S.M., Scott N., Cross D., Sagar P., Lewis F.A., Blair G.E., Taylor G.R., Dixon M.F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104:57–64. - PubMed
    1. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988;319:525–532. - PubMed
    1. Kranenburg O. The KRAS oncogene: Past, present, and future. Biochim. Biophys. Acta. 2005;1756:81–82. - PubMed

MeSH terms